Open Access<p>Elevated levels of pre-treatment lactate dehydrogenase are an unfavorable predictor factor in patients with EML4-ALK rearrangement non-small cell lung cancer treated with crizotinib</p>
Author(s) -
Hui Liang,
Di Ma,
Yixin Xu,
Jing Zhao,
Minjiang Chen,
Xiaoyan Liu,
Wei Zhong,
Junling Li,
Mengzhao Wang
Publication year - 2019
Publication title -
cancer management and research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.024
H-Index - 40
ISSN - 1179-1322
DOI - 10.2147/cmar.s213572
Subject(s) - crizotinib , medicine , anaplastic lymphoma kinase , lung cancer , lactate dehydrogenase , gastroenterology , oncology , alk inhibitor , univariate analysis , proportional hazards model , biology , biochemistry , multivariate analysis , malignant pleural effusion , enzyme
Targeted therapy is an important treatment for advanced non-small cell lung cancer (NSCLC) patients with specific genetic mutations, crizotinib can prolong survival in advanced NSCLC patients with echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK) rearrangement. We performed a retrospective analysis to investigate the association between the lactate dehydrogenase (LDH) levels and progression-free survival (PFS) in patients with EML4-ALK rearrangement NSCLC receiving treatment with crizotinib.